Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PRMT5 promotes cancer cell migration and invasion through the E2F pathway
Wojciech Barczak, Jin Li, Simon M. Carr, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 7
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response
Wojciech Barczak, Simon M. Carr, Geng Liu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 68
Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies
Jiahong Zheng, Bang Li, Yingqi Wu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8407-8427
Closed Access | Times Cited: 35
The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality
C. M. Bray, Cristina Balcells, Iain A. McNeish, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 16
Medicinal chemistry strategies targeting PRMT5 for cancer therapy
Siyu Fu, Qinwen Zheng, Dan Zhang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114842-114842
Closed Access | Times Cited: 27
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
Xuelian Liu, Anjin Wang, Yuying Shi, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1217-1217
Open Access | Times Cited: 13
Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors
Eunji Hong, Wojciech Barczak, Sujin Park, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 2
Open Access | Times Cited: 13
PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo
Elizabeth Brown, Leire Balaguer‐Lluna, Adam P. Cribbs, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy
Ian Sarvary, Mikkel Vestergaard, Loris Moretti, et al.
Journal of Medicinal Chemistry (2025)
Open Access
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
Shelby Sloan, Fiona Brown, Mackenzie Long, et al.
Blood (2023) Vol. 142, Iss. 10, pp. 887-902
Open Access | Times Cited: 11
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma
Tian Xia, Ming Liu, Quan Zhao, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 10
Open Access | Times Cited: 26
Prmt5 deficiency inhibits CD4+ T-cell Klf2/S1pr1 expression and ameliorates EAE disease
Yingxia Zheng, Zheyi Chen, Bingqian Zhou, et al.
Journal of Neuroinflammation (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 9
Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy
Qinju He, Yuanzhen Zhang, Wenchao Li, et al.
Cancer Letters (2024) Vol. 602, pp. 217214-217214
Closed Access | Times Cited: 3
Integrin αvβ3 Engagement Regulates Glucose Metabolism and Migration through Focal Adhesion Kinase (FAK) and Protein Arginine Methyltransferase 5 (PRMT5) in Glioblastoma Cells
Pulin Che, Lei Yu, Gregory K. Friedman, et al.
Cancers (2021) Vol. 13, Iss. 5, pp. 1111-1111
Open Access | Times Cited: 18
Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy
Zhiwei Cui, Fan Zou, Rongli Wang, et al.
World Journal of Surgical Oncology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 7
Posttranslational modifications of E2F family members in the physiological state and in cancer: Roles, mechanisms and therapeutic targets
Mingyang Sun, Yitong Ji, Guo‐Jun Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117147-117147
Open Access | Times Cited: 2
PROTACs in Gynecological Cancers: Current Knowledge and Future Potential as a Treatment Strategy
Fatemeh Movahed, Zahra Ourang, Razieh Neshat, et al.
Pathology - Research and Practice (2024) Vol. 263, pp. 155611-155611
Closed Access | Times Cited: 2
Cancer synthetic vulnerabilities to protein arginine methyltransferase inhibitors
Ernesto Guccione, Megan Schwarz, Federico Di Tullio, et al.
Current Opinion in Pharmacology (2021) Vol. 59, pp. 33-42
Open Access | Times Cited: 17
PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma
Devendra Kumar, Stuti Jain, Donald W. Coulter, et al.
Cancers (2023) Vol. 15, Iss. 24, pp. 5855-5855
Open Access | Times Cited: 6
Medicinal chemistry insights into PRMT5 inhibitors
Zhihao Jiao, Yongmi Huang, Kexin Gong, et al.
Bioorganic Chemistry (2024), pp. 107859-107859
Closed Access | Times Cited: 1
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Yaxun Guo, Yuzhan Li, Zhongmei Zhou, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 1
The Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma
Tanner Wright, Yalong Wang, Mark T. Bedford
Epigenomes (2021) Vol. 5, Iss. 1, pp. 2-2
Open Access | Times Cited: 11
Silencing of RAB42 down-regulated PD-L1 expression to inhibit the immune escape of hepatocellular carcinoma cells through inhibiting the E2F signaling pathway
Junjie Kong, Xiting Wang, Jianlu Wang, et al.
Cellular Signalling (2023) Vol. 108, pp. 110692-110692
Closed Access | Times Cited: 3
Research Progress on Small-molecule Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5) for Treating Cancer
Guo Chaohua, Lintao Wu, Xumei Zheng, et al.
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 21, pp. 2048-2074
Closed Access | Times Cited: 3
Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis
Zhenzhen Liang, Lianchang Liu, Chaowei Wen, et al.
Cancer Control (2021) Vol. 28
Open Access | Times Cited: 8
Machine-Learning-Based m5C Score for the Prognosis Diagnosis of Osteosarcoma
Haijie Zhang, Peipei Xu, Y Song
Journal of Oncology (2021) Vol. 2021, pp. 1-11
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top